Hepatitis B vaccination and booster in predialysis patients: a 4-year analysis.

Journal Article (Clinical Trial;Journal Article)

Patients undergoing chronic haemodialysis are at increased risk for infection with hepatitis B virus (HBV), but response to currently available vaccines is suboptimal. We undertook a 4-year prospective study of the efficacy of hepatitis B vaccine in patients with renal insufficiency, who were not yet dialysis-dependent. A booster dose of Recombivax HB was given at 3 or 4 years to those whose antibody levels fell below a predetermined point. Progression to dialysis was associated with poorer initial response to vaccination compared with those remaining dialysis-independent, but response to booster immunization was favourable in both groups. It is concluded that immunization of predialysis patients and subsequent booster vaccine results in a more favourable antibody response than has been seen historically in haemodialysis patients. Local endemicity and cost of vaccine should be considered when determining the best strategy for HBV immunization of patients with chronic renal failure.

Full Text

Duke Authors

Cited Authors

  • Dukes, CS; Street, AC; Starling, JF; Hamilton, JD

Published Date

  • September 1993

Published In

Volume / Issue

  • 11 / 12

Start / End Page

  • 1229 - 1232

PubMed ID

  • 8256504

International Standard Serial Number (ISSN)

  • 0264-410X

Digital Object Identifier (DOI)

  • 10.1016/0264-410x(93)90047-2


  • eng

Conference Location

  • Netherlands